Convivia

Convivia was a biotechnology company based in San Francisco that focused on developing therapies to extend human healthspan by targeting the biological drivers of aging. The company's primary research centered on the enzyme CD38, which is known to increase with age and deplete nicotinamide adenine dinucleotide (NAD+), a critical coenzyme for cellular metabolism and DNA repair. Convivia's lead program involved the development of potent, selective small molecule inhibitors of CD38 designed to restore NAD+ levels and improve metabolic health in aging populations. Founded in 2019 and backed by Y Combinator, the company aimed to translate longevity science into accessible therapeutic interventions. Although the company was part of the emerging longevity biotechnology sector, it ceased operations in late 2021.